Volume 96, Issue 1, Pages (July 1989)

Slides:

Advertisements

Similar presentations

Volume 32, Issue 1, Pages (July 1957)

Advertisements

Volume 32, Issue 1, Pages (July 1957)

Volume 95, Issue 2, Pages (February 1989)

Volume 136, Issue 1, Pages (July 2009)

Tell-tale Telangiectasias

Volume 104, Issue 2, Pages (August 1993)

Colloquium on Therapy of Right Heart Failure

Volume 77, Issue 5, Pages (May 1980)

Aortic Root Replacement in a Patient With Vancomycin-Resistant Enterococcus faecium Endocarditis and Leukemia Igor E. Konstantinov, MD, Kenton J. Zehr,

Tight Blood Glucose Control With Insulin in the ICU

When to Be Rash About a Fever and Headache

Volume 56, Issue 1, Pages (July 1969)

Angel López Rodríguez, M.D. CHEST

Volume 105, Issue 1, Pages (January 1994)

Timothy W. Higenbottam, MD, FCCP, Elizabeth A. Laude, PhD CHEST

Hyperbaric Oxygenation in Cardiac and Pulmonary Disease

Volume 127, Issue 6, Pages (June 2005)

Air Pollution and Chest Disease

Rheumatic Heart Disease in East Pakistan

Navin K. Jain, MD, Thiam H. Lie, MD, FCCP CHEST

Volume 80, Issue 6, Pages (December 1981)

Clinical and Personality Profiles and Survival in Patients With COPD

Utility of Pneumonotomy in the Treatment of Cavitary Lung Disease

Effects of Prostaglandin E1 on Oxygen Delivery and Consumption in Patients with the Adult Respiratory Distress Syndrome Henry J. Silverman, M.D., F.C.C.P.

Oxygen Therapy Titrated to Raise Mixed Venous Oxygen Content in COPD

Valve Drainage of the Pleural Cavity

Eulo Lupi-Herrera, M.D., David Bialostozky, M.D., Angel Sobrino, M.D.

Glen L. Prosise, B.A., Richard B. Berry, M.D., F.C.C.P. CHEST

Frank W. Ewald, MD, FCCP, Albert H. Scherff, MD CHEST

Mortality and Apnea Index in Obstructive Sleep Apnea

COUNTERPOINT: Is the Apnea-Hypopnea Index the Best Way to Quantify the Severity of Sleep-Disordered Breathing? No Naresh M. Punjabi, MD, PhD, FCCP CHEST

Managing Information Overload

Volume 142, Issue 1, Pages (July 2012)

Krishman. Padmanabhan, M.D., F.C.C.P., Santi R. Dhar, M.D., F.C.C.P

Has the 6-Min Walk Distance Run Its Course?

Airway Stenting for Patients With Benign Airway Disease and the Food and Drug Administration Advisory Lund Mark E. , MD, FCCP, Force Seth , MD, FCCP

Volume 74, Issue 5, Pages (November 1978)

Bronchospasm Secondary to Replacement Estrogen Therapy

Sleep Apnea, Hypothyroidism and Pulmonary Edema

Point: Should Medicare Allow Respiratory Therapists to Independently Practice and Bill for Educational Activities Related to COPD? Yes Thomas M. Fuhrman,

PEEP, Auto-PEEP, and Waterfalls

Volume 104, Issue 1, Pages 1-2 (July 1993)

New CHEST Associate Editors Named

Point: Adherence to Early Goal-Directed Therapy

What Went Right Lewis A. Eisen, MD, FCCP, Richard H. Savel, MD CHEST

Imaging for the Management of Community-Acquired Pneumonia

Spread the Word About CHEST in 2015

POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management

Brahms' Lullaby Revisited

Augusto Miyashiro, M.D., Soul J. Grosberg, M.D., Simon Wapnick, M.D.

Volume 138, Issue 4, Pages (October 2010)

Chemical Pneumonitis Due to Exposure to Bromine Compounds

Evolution in Reimbursement for Sleep Studies and Sleep Centers

Survival After an ICU Hospitalization for Pulmonary Hypertension

Bedside Calibration Of Pulmonary Artery Catheters

Traumatic Diaphragmatic Hernia Presenting as a Chest Wall Mass

Invasive Pulmonary Aspergillosis

Pulmonary Manifestations in a Case of Multiple Myeloma

A Single Nasal Prong for Continuous Oxygen Therapy

Myocardial Sarcoidosis Unresponsive to Steroids

Volume 42, Issue 2, Pages (August 1962)

Calcification of the Coronary Artery

Thoracic Surgery Survey on Lung Cancer Management

Digitalis and Angina Pectoris

Volume 133, Issue 4, Pages (April 2008)

Use of Endobronchial Ultrasound for Bedside Diagnosis of Acute Pulmonary Embolism in a Critically Ill Patient Colleen L. Channick, MD, FCCP, Richard.

POINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? Yes

Hyperventilation Syndrome

Richard G. Masson, M.D., F.C.C.P., Luke G. Tedeschi, M.D. CHEST

New Members of the Editorial Board

Presentation transcript:

Volume 96, Issue 1, Pages 114-119 (July 1989) Randomized Double-Blind, Multicenter Study of Prostaglandin E1 in Patients with the Adult Respiratory Distress Syndrome Roger C. Bone, M.D., F.C.C.P., Gus Slotman, M.D., Richard Maunder, M.D., F.C.C.P., Henry Silverman, M.D., F.C.C.P., Thomas M. Hyers, M.D., F.C.C.P., Morris D. Kerstein, M.D., Joseph J. Ursprung, M.D. CHEST Volume 96, Issue 1, Pages 114-119 (July 1989) DOI: 10.1378/chest.96.1.114 Copyright © 1989 The American College of Chest Physicians Terms and Conditions

Figure 1 Survival curve for the 50 PGE1-treated patients and 50 placebo-treated patients. Survival days are counted from the start of infusion. The + indicates the last date of contact for individual patients—they are counted as survivors. CHEST 1989 96, 114-119DOI: (10.1378/chest.96.1.114) Copyright © 1989 The American College of Chest Physicians Terms and Conditions

Figure 2 Mean change of systemic vascular resistance index from baseline (study day 0.). In this and subsequent figures, PGE1 (•) or placebo (○) was infused for 7 days or until the patient died. The reading on study day 0 is just prior to the start of infusion and on study day 8 is a post-infusion value. The abscissa is the mean change from baseline for all patients surviving that day. Vertical bars represent standard error of the mean. CHEST 1989 96, 114-119DOI: (10.1378/chest.96.1.114) Copyright © 1989 The American College of Chest Physicians Terms and Conditions

Figure 3 Mean change of mean arterial pressure from baseline. In this and subsequent figures* = p<0.05 and ** = p<0.01 between the two treatment groups. PGE1 (•) or placebo (○), as in Figure 2. CHEST 1989 96, 114-119DOI: (10.1378/chest.96.1.114) Copyright © 1989 The American College of Chest Physicians Terms and Conditions

Figure 4 Mean change of cardiac output from baseline. PGE1 (•) or placebo (○), as in Figure 2. CHEST 1989 96, 114-119DOI: (10.1378/chest.96.1.114) Copyright © 1989 The American College of Chest Physicians Terms and Conditions

Figure 5 Mean change of pulmonary vascular resistance index from baseline. PGE1 (•) or placebo, as in Figure 2. CHEST 1989 96, 114-119DOI: (10.1378/chest.96.1.114) Copyright © 1989 The American College of Chest Physicians Terms and Conditions

Figure 6 Mean change of oxygen availability index from baseline. O2Avl = CI(CaO2). CI = cardiac index. PGE1 (•) or placebo (○), as in Figure 2. CHEST 1989 96, 114-119DOI: (10.1378/chest.96.1.114) Copyright © 1989 The American College of Chest Physicians Terms and Conditions

Figure 7 Mean change of oxygen consumption index from baseline. Vo2I=CI(CaO2-CvO2). PGE1 (•) or placebo, as in Figure 2. CHEST 1989 96, 114-119DOI: (10.1378/chest.96.1.114) Copyright © 1989 The American College of Chest Physicians Terms and Conditions

Figure 8 Relationship of mean change of oxygen consumption to oxygen availability at each study day through day 8. PGE1 (•) or placebo, as in Figure 2. CHEST 1989 96, 114-119DOI: (10.1378/chest.96.1.114) Copyright © 1989 The American College of Chest Physicians Terms and Conditions